Maxcyte (MXCT) Price to Book (2021 - 2026)

Maxcyte (MXCT) has reported Price to Book for 6 consecutive years, with 0.82 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Book fell 32.51% year-over-year to 0.82 in Q2 2026; TTM through Jun 2026 was 0.82, a 32.51% decrease from a year earlier, with the FY2025 full-year figure at 0.97, down 54.73% from the prior year.
• Price to Book was 0.82 for Q2 2026 at Maxcyte, up from 0.45 in the prior quarter.
• Over five years, Price to Book peaked at 2.71 in Q1 2022 and troughed at 0.45 in Q1 2026.
• A 5-year average of 1.7 and a median of 1.89 in 2022 frame the typical range for Price to Book.
• Across the five-year window, Price to Book jumped 38.72% in 2024 and tumbled 69.2% in 2026, its largest moves.
• Over 5 years, Price to Book stood at 2.2 in 2022, then declined by 4.4% to 2.1 in 2023, then increased by 1.31% to 2.13 in 2024, then tumbled by 54.73% to 0.97 in 2025, then decreased by 14.8% to 0.82 in 2026.
• The last three Price to Book figures came in at 0.82 (Q2 2026), 0.45 (Q1 2026), and 0.97 (Q4 2025), per Business Quant data.